Develops antibody drugs designed to direct immune cells against solid tumors, including ovarian, pancreatic and bladder cancers.
10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our…View ↗
CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight…View ↗
CT-95 is an MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane…View ↗
CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of…View ↗
No revenue reported yet.
10-K for FY2024, filed Mar 20, 2025
10-Q for Q3 FY2026, filed Nov 10, 2026
−$7.6MView ↗
8-K, filed Jul 31, 2026
The Notification Letter provides an initial 180 calendar day period, or until January 25, 2027, in which to regain compliance, pursuant to…View ↗
8-K, filed Jun 15, 2026
At active dose levels, CTIM-76 produced a favorable safety profile that is consistent with the expected mechanism of action for a T cell…View ↗
Pipeline refocus
The older report described a progesterone-receptor drug for female cancers alongside an antibody candidate targeting a tumor protein, and said it was exploring options for the former. The latest report describes antibody candidates targeting solid tumors.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our…View ↗
CT-95 is an MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane…View ↗
CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of…View ↗
Competes with Beigene, Third Arc Bio, Xencor, Daiichi Sankyo, BioNTech, TORL, Amgen, RemeGen Biosciences, Outpace Bio, Navrogen, Bicycle Therapeutics, Pfizer, Eli Lilly, Corbus Pharmaceuticals, Bio-Thera, Mabwell, Adcentrx, Aktis Oncology, and Shanghai Henlius Biotech
10-K for FY2025, filed Mar 23, 2026For CTIM-76, our CLDN6 x CD3 TCE, we are aware of several companies developing T cell engagers against CLDN6. Several TCE candidates are…View ↗
Loading...